Table 1 Comprehensive overview of the study groups, with baseline and follow-up parameters in all modalities

From: Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment

   

Imaging

Histology

Biochemistry

Study group

Age months (scan)

Weight g±s.d.

n

SUVRCTX/CBL±s.d.

Δ%-SUVRCTX/CBL±s.d. vs BL

Δ%-SUVRCTX/CBL±s.d. vs FU1

Plaque load (percentage area ±s.e.m.)

Plaque load (percentage area ±s.e.m.) COVAR

Plaque density (N per mm 3 ±s.e.m.)

Plaque density (N per mm 3 ±s.e.m.) COVAR

Aβ 38 (ng ml −1 ±s.e.m.)

Aβ 38 (ng ml −1 ±s.e.m.) COVAR

Aβ 40 (ng ml −1 ±s.e.m.)

Aβ 40 (ng ml −1 ±s.e.m.) COVAR

Aβ 42 (ng ml −1 ±s.e.m.)

Aβ 42 (ng ml −1 ±s.e.m.) COVAR

Aβ tot (ng ml −1 ±s.e.m.)

Aβ tot (ng ml −1 ±s.e.m.) COVAR

APP-Swe (RO5506284)

12 (BL)

27.2±3.2

12

1.00±0.05

              
 

16 (FU1)

26.8±2.5

12

1.01±0.06

+1.7±3.9%

             
 

18 (FU2)

27.7±2.6

11

1.03±0.10a

+2.6±6.1%b

+0.9±6.5%a

3.4±1.0

2.6±0.5a

70.3±21.2

55.8±12.6a

13±4

10±2

146±50

116±33

39±10a

32±6b

198±63

158±40

APP-Swe (vehicle)

12 (BL)

26.4±2.4

11

0.96±0.04

              
 

16 (FU1)

26.5±1.7

11

1.03±0.05

+6.7±6.8%

             
 

18 (FU2)

26.3±1.5

9

1.13±0.08

+17.1±6.9%

+10.1±9.7%

3.6±0.6

4.5±0.6

90.7±11.3

107.9±12.4

11±2

15±2

138±24

174±30

65±5

73±6

214±28

261±35

C57BL/6 (RO5506284)

12 (BL)

24.6±1.1

11

1.02±0.05

              
 

16 (FU1)

26.4±1.2

10

1.00±0.06

−2.1±2.9%

             
 

18 (FU2)

26.7±1.2

10

0.99±0.06

−2.6±3.3%

−0.3±2.9%

            

C57BL/6 (vehicle)

12 (BL)

24.2±1.1

12

1.01±0.06

              
 

16 (FU1)

24.8±1.5

11

1.03±0.04

+2.6±3.9%

             
 

18 (FU2)

25.5±1.1

11

1.02±0.04

+2.0±3.6%

−0.7±2.7%

            
  1. Abbreviations: BL, baseline; COVAR, covariate; FU1, follow-up 1; FU2, follow-up 2; SUVR, standard-uptake-value ratios.
  2. Column 5 indicates the Aβ-PET SUVRCTX/CBL value for each scan time (baseline, follow-up 1, follow-up 2 (termination) scans), whereas column 6 indicates Δ%-SUVRCTX/CBL between follow-up and termination scans relative to the baseline value, and column 7 indicates Δ%-SUVRCTX/CBL between follow-up 1 and follow-up 2 results. Histochemically determined plaque load and plaque density of one brain hemisphere with and without including the PET baseline estimate as a covariate (COVAR) are presented in columns 8–11. Biochemical determination of insoluble Aβ38, Aβ40, Aβ42 and Aβtot concentrations in the other brain hemisphere with and without including the PET baseline estimate as a COVAR are presented in columns 12–19.
  3. astatistically significant at P<0.05.
  4. bstatistically significant at P<0.001 for the contrast of TG-GSM and TG-VEH mice.
Back to article page